Skip to main content
European Commission logo print header

A novel Androgen Synthesis Pathway in treatment-REsistant Prostate Cancer

Obiettivo

Prostate cancer (PC) is the most prevalent non-cutaneous cancer in men and leads to high morbidity and mortality. Disseminated PC is treated by hormonal treatment in order to block intratumoral activation of the androgen receptor (AR) by 5α-dihydrotestosterone (DHT). Despite this treatment, eventually all patients develop castration-resistant disease (CRPC) which is accompanied by poor prognosis. Novel androgen synthesis and receptor inhibitors improve patient survival in CRPC, demonstrating the crucial role of residual androgen presence in PC despite castration.
Besides the classic DHT synthesis pathway through testosterone, recent studies in humans have shown formation of DHT through an alternative pathway that does not require testosterone as an intermediate. Activity of this alternative androgen synthesis pathway is dependent on the presence of specific steroidogenic enzymes. Results of preliminary preclinical and clinical research show that levels of alternative pathway intermediates are increased in CRPC.
Our goal is to investigate the activity and relevance of this novel pathway during progression of PC. The contribution of the alternative pathway to DHT-initiated AR activation will be explored using previously established in vitro models and sensitive steroid detection methods. This translational study will serve to discover novel targets for inhibition of intratumoral DHT synthesis and subsequent (CR)PC growth.

Invito a presentare proposte

FP7-PEOPLE-2013-IEF
Vedi altri progetti per questo bando

Coordinatore

THE UNIVERSITY OF BIRMINGHAM
Contributo UE
€ 110 803,20
Indirizzo
Edgbaston
B15 2TT Birmingham
Regno Unito

Mostra sulla mappa

Regione
West Midlands (England) West Midlands Birmingham
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Xavier Rodde (Mr.)
Collegamenti
Costo totale
Nessun dato